Literature DB >> 32481380

Efficacy and safety of Chinese herbal medicine for Coronavirus disease 2019: A protocol for systematic review and meta-analysis.

Maoyi Yang1, Zhipeng Hu, Rensong Yue.   

Abstract

BACKGROUND: Coronavirus disease 2019 (COVID-19) is a global pandemic caused by the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). There is no specific cure for this disease, and the clinical management mainly depends on supportive treatment. Traditional Chinese medicines (CHM) is widely used in treating COVID-19 in China.
METHODS: A comprehensive literature search will be conducted. Two methodological trained researchers will read the title, abstract, and full texts and independently select the qualified literature according to inclusion and exclusion criteria. After assessment of the risk of bias and data extraction, we will conduct meta-analyses for outcomes related to COVID-19. The heterogeneity of data will be investigated by Cochrane χ and I tests. Then publication bias assessment will be conducted by funnel plot analysis and Egger test.
RESULTS: The results of our research will be published in a peer-reviewed journal.
CONCLUSION: Our study aims to systematically present the clinical evidence of CHM in the treatment of COVID-19, which will be of guiding significance for further research and clinical practice. OSF REGISTRATION NUMBER: 10.17605/OSF.IO/H7GMU.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32481380     DOI: 10.1097/MD.0000000000020157

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  2 in total

1.  Ozone as an adjuvant therapy for COVID-19: A systematic review and meta-analysis.

Authors:  David Setyo Budi; Ihsan Fahmi Rofananda; Nando Reza Pratama; Henry Sutanto; Arisvia Sukma Hariftyani; Saskia Ratna Desita; Aulia Zinedinita Rahmasari; Tri Pudy Asmarawati; Langgeng Agung Waskito; Citrawati Dyah Kencono Wungu
Journal:  Int Immunopharmacol       Date:  2022-07-04       Impact factor: 5.714

2.  Safety and efficacy of ozone therapy in mild to moderate COVID-19 patients: A phase 1/11 randomized control trial (SEOT study).

Authors:  Mili Shah; Jignasha Captain; Vidyadhar Vaidya; Arvind Kulkarni; Kedar Valsangkar; Pradeep M K Nair; Gayatri Ganu
Journal:  Int Immunopharmacol       Date:  2020-12-23       Impact factor: 5.714

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.